Navigation Links
AMICAS Announces Integrations at More Than 100 MEDITECH Facilities

Vision Series PACS milestone is a testament to tight integration and

excellent value

BOSTON, May 27 /PRNewswire-FirstCall/ -- AMICAS, Inc. (Nasdaq: AMCS), a leader in radiology and medical image and information management solutions, today announced that it has successfully integrated its Vision Series(TM) PACS at more than 100 facilities that use MEDITECH(TM) as their health information system. AMICAS will be showcasing Vision Series PACS at the 2008 International Medical Users Software Exchange (MUSE) Conference in Dallas, TX, from May 27 to 30. AMICAS will be in booth #530.

(Logo: )

"AMICAS has a proven track record of successfully implementing our PACS at more than 100 MEDITECH facilities across the country," said Paul Merrild, vice president of marketing at AMICAS. "Many facilities throughout the country have made an investment in MEDITECH -- and AMICAS allows them to fully leverage their investment when they choose our Vision Series PACS."

AMICAS is focused on developing solutions that allow facilities running a MEDITECH health information system to realize superior integration and value from their investment with MEDITECH. Complementing MEDITECH's core applications, the AMICAS product suite includes the following functionality:

-- Vision Series PACS offers the capability to securely launch an

encrypted image viewer that is embedded within numerous MEDITECH

products, including PCI and EMR. This allows users in other MEDITECH

applications to be "image-aware" without disrupting their daily

workflow, seamlessly launching the AMICAS products on an as-needed


-- Vision Watch(TM) offers reporting functionality that complements the

tools found in the MEDITECH RIS. These capabilities empower radiology

administrators with easily accessible information required to run their

departments and facilities effectively, such as data on referring

physician volume reports, imaging equipment utilization, and HIPAA

reporting needs -- all in a Web-based, drill-down, "point and click"

user interface.

-- Vision Series PACS includes a bi-directional interface with all

MEDITECH platforms. This interface returns relevant clinical data to

radiologists at their PACS workstations in order to enhance their

ability to diagnose their patients, thus increasing their efficiency

and that of the entire radiology department or facility.

"AMICAS' dedication to making MEDITECH customers successful extends beyond technical capabilities. We have invested, and will continue to invest, in products and services that complement those provided by MEDITECH. We focus on being collaborative and cooperative with MEDITECH for the benefit of our mutual customers. We believe this focus differentiates us from other PACS companies in the market," said Mr. Merrild.

AMICAS, Vision Series, and Vision Watch are trademarks or registered trademarks of AMICAS, Inc. All other company and trademark names are the property of their respective owners.

About AMICAS, Inc.

AMICAS, Inc. ( is a leader in radiology and medical image and information management solutions. The AMICAS(R) Vision Series(TM) products provide a complete, end-to-end solution for imaging centers, ambulatory care facilities, and radiology practices. Acute care and hospital clients are provided a fully-integrated, HIS/RIS-independent PACS, featuring advanced enterprise workflow support and scalable design. Complementing the Vision Series product family is AMICAS Insight(TM) Solutions, a set of client- centered professional and consulting services that assist our customers with a well-planned transition to a digital enterprise.


Aine Cryts

Marketing Communications Manager


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
2. AMICAS to Present at CIBC World Markets 18th Annual Healthcare Conference
3. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
4. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
5. NicOx Announces Departure of Damian Marron for CEO Position
6. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
7. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
8. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
11. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):